Bryce B Reeve1, Molly McFatrich2, Laura C Pinheiro3, David R Freyer4, Ethan M Basch2, Justin N Baker5, Janice S Withycombe6, Lillian Sung7, Jennifer W Mack8, Mia K Waldron9, Catriona Mowbray10, Diana Palma4, Pamela S Hinds11. 1. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA; Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA. Electronic address: bbreeve@email.unc.edu. 2. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA. 3. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA; Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA. 4. Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California, USA. 5. Division of Quality of Life and Palliative Care, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. 6. Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia, USA. 7. Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada; Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada. 8. Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 9. Department of Nursing Research and Quality Outcomes, Children's National Health System, Washington, District of Columbia, USA. 10. Department of Oncology, Children's National Health System, Washington, District of Columbia, USA. 11. Department of Nursing Research and Quality Outcomes, Children's National Health System, Washington, District of Columbia, USA; Department of Pediatrics, George Washington University, Washington, District of Columbia, USA.
Abstract
CONTEXT: The National Cancer Institute created the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) to allow direct input on symptomatic adverse events (AEs) from adult patients in oncology trials. OBJECTIVES: This study sought to determine the youngest age to complete the PRO-CTCAE, evaluated comprehension of PRO-CTCAE among adolescents, tested new items not currently in PRO-CTCAE, and tested a parent-proxy version. METHODS: From seven pediatric cancer hospitals, 51 adolescents (13-20 years) receiving cancer treatment participated, along with 40 parent proxies. We evaluated 55 AEs from the PRO-CTCAE library (97 questions) and seven new AEs not in PRO-CTCAE that assess symptom frequency, severity, interference, or presence. Questions were distributed across three forms to reduce burden. Cognitive interviews with retrospective probing were completed in age groups of 13-15 and 16-20 year olds. Proxies were interviewed independently. RESULTS: In general, the 16-20 year olds and the parent proxies were able to understand and complete the PRO-CTCAE and newly designed AE questions. Five PRO-CTCAE terms (bloating of the abdomen, anxiety, flashing lights in front of your eyes, hot flashes, and bed sores) and the wording of the questions about AE severity were challenging for a few adolescents and proxies. The 13-15 year olds had greater challenges completing the PRO-CTCAE. CONCLUSION: This study extends use of the adult PRO-CTCAE for adolescents as young as 16 years and proposes new questions for seven new symptomatic AEs and a parent-proxy version of PRO-CTCAE. Additional testing of the new questions and alternative language for more challenging PRO-CTCAE items is recommended in adults.
CONTEXT: The National Cancer Institute created the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) to allow direct input on symptomatic adverse events (AEs) from adult patients in oncology trials. OBJECTIVES: This study sought to determine the youngest age to complete the PRO-CTCAE, evaluated comprehension of PRO-CTCAE among adolescents, tested new items not currently in PRO-CTCAE, and tested a parent-proxy version. METHODS: From seven pediatric cancer hospitals, 51 adolescents (13-20 years) receiving cancer treatment participated, along with 40 parent proxies. We evaluated 55 AEs from the PRO-CTCAE library (97 questions) and seven new AEs not in PRO-CTCAE that assess symptom frequency, severity, interference, or presence. Questions were distributed across three forms to reduce burden. Cognitive interviews with retrospective probing were completed in age groups of 13-15 and 16-20 year olds. Proxies were interviewed independently. RESULTS: In general, the 16-20 year olds and the parent proxies were able to understand and complete the PRO-CTCAE and newly designed AE questions. Five PRO-CTCAE terms (bloating of the abdomen, anxiety, flashing lights in front of your eyes, hot flashes, and bed sores) and the wording of the questions about AE severity were challenging for a few adolescents and proxies. The 13-15 year olds had greater challenges completing the PRO-CTCAE. CONCLUSION: This study extends use of the adult PRO-CTCAE for adolescents as young as 16 years and proposes new questions for seven new symptomatic AEs and a parent-proxy version of PRO-CTCAE. Additional testing of the new questions and alternative language for more challenging PRO-CTCAE items is recommended in adults.
Authors: Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring Journal: Value Health Date: 2011-10-10 Impact factor: 5.725
Authors: Ethan M Basch; Bryce B Reeve; Sandra A Mitchell; Stephen B Clauser; Lori Minasian; Laura Sit; Ram Chilukuri; Paul Baumgartner; Lauren Rogak; Emily Blauel; Amy P Abernethy; Deborah Bruner Journal: Cancer J Date: 2011 Jul-Aug Impact factor: 3.360
Authors: Katherine B Bevans; Anne W Riley; JeanHee Moon; Christopher B Forrest Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2010-08 Impact factor: 2.217
Authors: Bryce B Reeve; Janice S Withycombe; Justin N Baker; Mary C Hooke; Jessica C Lyons; Catriona Mowbray; Jichuan Wang; David R Freyer; Steven Joffe; Lillian Sung; Deborah Tomlinson; Stuart H Gold; Pamela S Hinds Journal: Pediatr Blood Cancer Date: 2013-01-17 Impact factor: 3.167
Authors: Andrew J Bukowinski; Karen C Burns; Kerry Parsons; John P Perentesis; Maureen M O'Brien Journal: Semin Oncol Nurs Date: 2015-05-07 Impact factor: 2.315
Authors: Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch Journal: Qual Life Res Date: 2013-07-20 Impact factor: 4.147
Authors: Benjamin Arnold; Sandra A Mitchell; Lauren Lent; Tito R Mendoza; Lauren J Rogak; Natalie M Barragán; Gordon Willis; Mauricio Medina; Suzanne Lechner; Frank J Penedo; Jay K Harness; Ethan M Basch Journal: Support Care Cancer Date: 2016-02-02 Impact factor: 3.603
Authors: Janice S Withycombe; Molly McFatrich; Laura Pinheiro; Pamela S Hinds; Frank G Keller; Justin N Baker; Jenny W Mack; Lillian Sung; Mia K Waldron; Bryce B Reeve Journal: Qual Life Res Date: 2019-01-17 Impact factor: 4.147
Authors: Bryce B Reeve; Molly McFatrich; Jennifer W Mack; Scott H Maurer; Shana S Jacobs; David R Freyer; Janice S Withycombe; Justin N Baker; Sharon M Castellino; Li Lin; Nicole R Lucas; Pamela S Hinds Journal: J Natl Cancer Inst Date: 2020-11-01 Impact factor: 13.506
Authors: Amy M Berkman; Karly M Murphy; Elizabeth J Siembida; Nancy Lau; Yimin Geng; Susan K Parsons; John M Salsman; Michael E Roth Journal: Value Health Date: 2021-08-08 Impact factor: 5.725
Authors: Allison Barz Leahy; Lisa A Schwartz; Yimei Li; Bryce B Reeve; Justin E Bekelman; Richard Aplenc; Ethan M Basch Journal: Cancer Date: 2021-05-04 Impact factor: 6.921
Authors: Pamela S Hinds; Meaghann S Weaver; Janice S Withycombe; Justin N Baker; Shana S Jacobs; Jennifer W Mack; Scott H Maurer; Molly McFatrich; Laura C Pinheiro; Bryce B Reeve; Jichuan Wang Journal: J Pain Symptom Manage Date: 2020-10-20 Impact factor: 5.576